Evidence map›Paper›PMID 42245560›Full record

ArticleFrontiers in nutrition2026

Efficacy of Ustekinumab combined with partial enteral nutrition in Crohn's disease.

Hanyu Yin, Chao Chen, Xiaowei Chen, Weixiang Yao, Chen Huang, Jiahe Chen, Mengying Zhu, Xiaoli Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hanyu Yin *Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Chao Chen *Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiaowei ChenDepartment of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Weixiang YaoDepartment of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Chen HuangDepartment of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jiahe ChenDepartment of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Mengying ZhuDepartment of Gastroenterology, Xianju County People's Hospital, Xianju, Zhejiang, China.
Xiaoli WuDepartment of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ustekinumab (UST) has emerged as an effective biological therapy for Crohn's disease (CD), yet many patients experience suboptimal long-term mucosal healing. Partial enteral nutrition (PEN) may enhance treatment outcomes by reducing intestinal inflammation and improving nutritional status. However, evidence regarding the combined use of UST and PEN remains limited. This study aims to investigate the effect of UST combined with PEN on therapeutic efficacy in CD patients. Methods: We conducted a single-center, retrospective cohort study including adult CD patients who received UST induction and maintenance therapy. Patients were stratified into a UST + PEN group and a UST monotherapy group according to whether ≥50% of their calculated daily energy intake was provided by PEN. Clinical outcomes (CDAI at weeks 8 and 24) and the primary endpoint endoscopic remission at week 54 (SES-CD < 3 without ulcers) were assessed. Multivariable logistic regression was used to identify independent predictors of endoscopic remission. Results: A total of 124 patients were included, with 38 receiving UST + PEN. Despite having lower BMI and higher baseline CDAI, the endoscopic remission rate at week 54 was significantly higher in the combination group (71.05% vs. 50.00%, Conclusion: Ustekinumab combined with partial enteral nutrition is associated with higher rates of endoscopic remission at week 54 in patients with Crohn's disease.

Indexed as

clinical remissionCrohn’s diseaseendoscopic remissionpartial enteral nutritionUstekinumab

Identifiers

PMID42245560
PMCPMC13229795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.